Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K. P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584).
Tanvetyanon
T
T
D001859:Bone Neoplasms / Q000473:pathology* / Q000556:secondary*; D019008:Drug Resistance, Neoplasm; D023381:Endpoint Determination; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D011788:Quality of Life; D015203:Reproducibility of Results; D013997:Time Factors